Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 5/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 5/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | SERPINH1 | P50454 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | NQO2 | P16083 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29746142 | 0.85 | CYP3A4 (0.36) | ALPLKDM4EALDH1A1 | |
| SCHEMBL29746110 | 0.81 | SLC6A3 (0.43) | NR4A2KDM4ESLC6A4SLC6A3PDK2 | |
| SCHEMBL30464605 | 0.73 | SOS1 (0.43) | NR4A2KDM4ESLC6A4SLC6A3PDK2 | |
| SCHEMBL25280246 | 0.73 | SOS1 (0.43) | NR4A2KDM4ESLC6A4SLC6A3PDK2 | |
| SCHEMBL30464600 | 0.73 | SOS1 (0.43) | NR4A2KDM4ESLC6A4SLC6A3PDK2 | |
| SCHEMBL29746168 | 0.72 | SLC6A3 (0.46) | NR4A2KDM4ESLC6A4SLC6A3PDK2 | |
| SCHEMBL25233707 | 0.72 | MGLL (0.41) | NR4A2KDM4ESLC6A4SLC6A3PDK2 | |
| SCHEMBL25612340 | 0.70 | ABL1 (0.51) | KDM4EABL1ALDH1A1HPGDHSD17B10 | |
| SCHEMBL25276617 | 0.70 | PRKAG1 (0.46) | SLC6A4SLC6A3SMN1; SMN2LMNA | |
| SCHEMBL31055692 | 0.70 | PRKAG1 (0.46) | SLC6A4SLC6A3SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3997096-B1 | NEW HETEROCYCLIC COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2024-08-28 | — | — | EP | disclosed |
| US-20220242876-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2022-08-04 | — | — | US | disclosed |
| EP-3997096-A1 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2022-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220242876-A1 | HETEROCYCLIC COMPOUNDS | CYP1B1, CYP1A1, CYP1A2 | ALPL 4110/4885NR4A2 1400/4885KDM4E 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.